Top

Virology Journal

Published in:

Open Access 01-12-2009 | Research

Oral vaccination with a recombinant Salmonella vaccine vector provokes systemic HIV-1 subtype C Gag-specific CD4+ Th1 and Th2 cell immune responses in mice

Authors: Nyasha Chin'ombe, William R Bourn, Anna-Lise Williamson, Enid G Shephard

Published in: Virology Journal | Issue 1/2009

Abstract

Background

Recombinant Salmonella vaccine vectors may potentially be used to induce specific CD4+ T cell responses against foreign viral antigens. Such immune responses are required features of vaccines against pathogens such as human immunodeficiency virus type 1 (HIV-1). The aim of this study was to investigate the induction of systemic HIV-1-specific CD4+ T helper (Th) responses in mice after oral immunization with a live attenuated Salmonella vaccine vector that expressed HIV-1 subtype C Gag. Groups of BALB/c mice were vaccinated orally three times (4 weeks apart) with this recombinant Salmonella. At sacrifice, 28 days after the last immunization, systemic CD4+ Th1 and Th2 cytokine responses were evaluated by enzyme-linked immunospot assay and cytometric bead array. HIV-1 Gag-specific IgG1 and IgG2a humoral responses in the serum were determined by enzyme-linked immunosorbent assay.

Results

Mice vaccinated with the recombinant Salmonella elicited both HIV-1-specific Th1 (interferon-gamma (IFN-γ) and tumour necrosis factor-alpha (TNF-α)) and Th2 (interleukin-4 (IL-4) and interleukin-5 (IL-5)) cytokine responses. The vaccine induced 70 (IFN-γ) spot-forming units (SFUs)/10e6 splenocytes and 238 IL-4 SFUs/10e6 splenocytes. Splenocytes from vaccinated mice also produced high levels of Th1 and Th2 cytokines upon stimulation with a Gag CD4 peptide. The levels of IFN-γ, TNF-α, IL-4 and IL-5 were 7.5-, 29.1-, 26.2- and 89.3-fold above the background, respectively. Both HIV-1 Gag-specific IgG1 and IgG2a antibodies were detected in the sera of vaccinated mice.

Conclusion

The study highlights the potential of orally-delivered attenuated Salmonella as mucosal vaccine vectors for HIV-1 Subtype C Gag to induce Gag-specific CD4+ Th1 and Th2 cellular immune responses and antibodies which may be important characteristics required for protection against HIV-1 infection.

Available only for authorised users

Fouts TR, Tuskan RG, Chada S, Hone DM, Lewis GK: Construction and immunogenicity of Salmonella typhimurium vaccine vectors that express HIV-1 gp120. Vaccine 1995, 13: 1697-1705.CrossRefPubMed

Dietrich G, Griot-Wenk M, Metcalfe IC, Lang AB, Viret JF: Experience with registered mucosal vaccines. Vaccine 2003, 21: 678-683.CrossRefPubMed

Capozzo AV, Cuberos L, Levine MM, Pasetti MF: Mucosally delivered Salmonella live vector vaccines elicit potent immune responses against a foreign antigen in neonatal mice born to naive and immune mothers. Infect Immun 2004, 72: 4637-4646.PubMedCentralCrossRefPubMed

Spreng S, Dietrich G, Weidinger G: Rational design of Salmonella -based vaccination strategies. Methods 2006, 38: 133-143.CrossRefPubMed

Hess J, Schaible U, Raupach B, Kaufmann SH: Exploiting the immune system: toward new vaccines against intracellular bacteria. Adv Immunol 2000, 75: 1-88.CrossRefPubMed

Mosmann TR, Sad S: The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today. 1986,17(3):138-146.CrossRef

Openshaw P, Murphy EE, Hosken NA, Maino V, Davis K, Murphy K, O'Garra A: Heterogeneity of intracellular cytokine synthesis at the single-cell level in polarized T helper 1 and T helper 2 populations. J Exp Med 1995, 182: 1357-1367.CrossRefPubMed

Sornasse T, Larenas PV, Davis KA, de Vries JE, Yssel H: Differentiation and stability of T helper 1 and 2 cells derived from naïve human neonatal CD4+ T cells, analyzed at the single-cell level. J Exp Med 1996, 184: 473-483.CrossRefPubMed

Hasenkrug KJ, Brooks DM, Dittmer U: Critical role for CD4(+) T cells in controlling retrovirus replication and spread in persistently infected mice. J Virol 1998, 72: 6559-6564.PubMedCentralPubMed

10.

Janssen EM, Lemmens EE, Wolfe T, Christen U, von Herrath MG, Schoenberger SP: CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 2003, 421: 852-856.CrossRefPubMed

11.

Rosenberg ES, Billingsley JM, Caliendo AM, Boswell SL, Sax PE, Kalams SA, Walker BD: Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 1997, 278: 1447-1450.CrossRefPubMed

12.

Khan SA, Stratford R, Wu T, Mckelvie N, Bellaby T, Hindle Z, Sinha KA, Eltze S, Mastroeni P, Pickard D, Dougan G, Chatfield SN, Brennan FR: Salmonella typhi and S typhimurium derivatives harbouring deletions in aromatic biosynthesis and Salmonella Pathogenicity Island-2 (SPI-2) genes as vaccines and vectors. Vaccine 2003, 21: 538-548.CrossRefPubMed

13.

Sambrook J, Maniatis T, Fritsch EF: Molecular cloning: a laboratory manual. 2nd edition. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York; 1989.

14.

Chin'ombe N, Bourn RW, Williamson A, Shepard EG: An oral recombinant Salmonella enteric serovar Typhimurium mutant elicits systemic antigen-specific CD8+ T cell cytokine responses in mice. Gut Pathogens 2009, 1: 9.PubMedCentralCrossRefPubMed

15.

Shephard E, Burgers WA, Van Harmelen JH, Monroe JE, Greenhalgh T, Williamson C, Williamson AL: A multigene HIV type 1 subtype C modified vaccinia Ankara (MVA) vaccine efficiently boosts immune responses to a DNA vaccine in mice. AIDS Res Hum Retroviruses 2008, 24: 207-217.CrossRefPubMed

16.

Bradley DJ, Ghori N, Falkov S: Salmonella Typhimurium initiates murine infection by penetrating and destroying the specialized epithelial M cells of the Peyer's patches. J Exp Med 1994, 180: 15-23.CrossRef

17.

Everest P, Wain J, Roberts M, Rook G, Dougan G: The molecular mechanisms of severe typhoid fever. Trends Microbiol 2001, 9: 316-320.CrossRefPubMed

18.

Huang Y, Hajishengallis G, Michalek SM: Induction of protective immunity against Streptococcus mutans colonization after mucosal immunization with attenuated Salmonella enterica serovar typhimurium expressing an S. mutans adhesin under the control of in vivo-inducible nirB promoter. Infect Immun 2001, 69: 2154-2161.PubMedCentralCrossRefPubMed

19.

Chen H, Schifferli DM: Construction, characterization, and immunogenicity of an attenuated Salmonella enterica serovar typhimurium pgtE vaccine expressing fimbriae with integrated viral epitopes from the spiC promoter. Infect Immun 2003, 71: 4664-4673.PubMedCentralCrossRefPubMed

20.

Salam MA, Katz J, Zhang P, Hajishengallis G, Michalek SM: Immunogenicity of Salmonella vector vaccines expressing SBR of Streptococcus mutans under the control of a T7-nirB (dual) promoter system. Vaccine 2006, 24: 5003-5015.CrossRefPubMed

21.

Zahn K: Overexpression of an mRNA dependent on rare codons inhibits protein synthesis and cell growth. J Bacteriol 1996, 178: 2926-2933.PubMedCentralPubMed

22.

Ejdeback M, Young S, Samuelsson A, Karlsson BG: Effects of codon usage and vector-host combinations on the expression of spinach plastocyanin in Escherichia coli . Protein Expr Purif 1997, 11: 17-25.CrossRefPubMed

23.

Baneyx F: Recombinant protein expression in Escherichia coli . Curr Opin Biotechnol 1999, 10: 411-421.CrossRefPubMed

24.

Kim S, Lee SB: Rare codon clusters at 5'-end influence heterologous expression of archaeal gene in Escherichia coli . Protein Expr Purif 2006, 50: 49-57.CrossRefPubMed

25.

Tsunetsugu-Yokota Y, Ishige M, Murakami M: Oral attenuated Salmonella enterica serovar Typhimurium vaccine expressing codon-optimized HIV type 1 Gag enhanced intestinal immunity in mice. AIDS Res Hum Retroviruses 2007, 23: 278-286.CrossRefPubMed

26.

Baud D, Ponci F, Bobst M, De Grandi P, Nardelli-Haefliger D: Improved efficiency of a Salmonella -based vaccine against human papillomavirus type 16 virus-like particles achieved by using a codon-optimized version of L1. J Virol 2004, 78: 12901-12909.PubMedCentralCrossRefPubMed

27.

Spreng S, Gentschev I, Goebel W, Weidinger G, Meulen V, Niewiesk S: Salmonella vaccines secreting measles virus epitopes induce protective immune responses against measles virus encephalitis. Microbes Infect 2000, 2: 1687-1692.CrossRefPubMed

28.

Svensson M, Stockinger B, Wick MJ: Bone marrow-derived dendritic cells can process bacteria for MHC-I and MHC-II presentation to T cells. J Immunol 1997, 158: 4229-4236.PubMed

29.

Yrlid U, Wick MJ: Salmonella -induced apoptosis of infected macrophages results in presentation of a bacteria-encoded antigen after uptake by bystander dendritic cells. J Exp Med 2000, 191: 613-624.PubMedCentralCrossRefPubMed

30.

Kalupahana RS, Mastroeni P, Maskell D, Blacklaws BA: Activation of murine dendritic cells and macrophages induced by Salmonella enterica serovar Typhimurium. Immunology 2005, 115: 462-472.PubMedCentralCrossRefPubMed

31.

Galdiero M, De Martino L, Marcatili A, Nuzzo I, Vitiello M, Cipollaro de l'Ero G: Th1 and Th2 cell involvement in immune response to Salmonella typhimurium porins. Immunology 1998, 94: 5-13.PubMedCentralCrossRefPubMed

32.

Pascual DW, Hone DM, Hall S, van Ginkel FW, Yamamoto M, Walters N, Fujihashi K, Powell RJ, Wu S, Vancott JL, Kiyono H, McGhee JR: Expression of recombinant enterotoxigenic Escherichia coli colonization factor antigen I by Salmonella typhimurium elicits a biphasic T helper cell response. Infect Immun 1999, 67: 6249-6256.PubMedCentralPubMed

33.

Kang HY, Curtiss R 3rd: Immune responses dependent on antigen location in recombinant attenuated Salmonella typhimurium vaccines following oral immunization. FEMS Immunol Med Microbiol 2003, 37: 99-104.CrossRefPubMed

34.

Jun S, Gilmore W, Callis G, Rynda A, Haddad A, Pascual DW: A live diarrheal vaccine imprints a Th2 cell bias and acts as an anti-inflammatory vaccine. J Immunol 2005, 175: 6733-6740.CrossRefPubMed

35.

Finkelman FD, Holmes J, Katona IM, Urban JF, Beckmann JP, Park LS, Schooley KA, Coffman RL, Mosmann TR, Paul WE: Lymphokine control of in vivo immunoglobulin isotype selection. Ann Rev Immunol 1990, 8: 303-333.CrossRef

36.

Spellberg B, Edwards JE Jr: Type 1/Type 2 immunity in infectious diseases. Clin Infect Dis 2001, 32: 76-102.CrossRefPubMed

37.

Stavnezer J: Antibody class switching. Adv Immunol 1996, 61: 79-146.CrossRefPubMed

38.

O'Garra A, Arai N: The molecular basis of T helper 1 and T helper 2 cell differentiation. Trends Cell Biol 2000, 10: 542-450.CrossRefPubMed

39.

Rüssmann H, Shams H, Poblete F, Fu Y, Galán JE, Donis RO: Delivery of epitopes by the Salmonella type III secretion system for vaccine development. Science 1998, 281: 565-568.CrossRefPubMed

40.

Chen LM, Briones G, Donis RO, Galán JE: Optimization of the delivery of heterologous proteins by the Salmonella enterica serovar Typhimurium type III secretion system for vaccine development. Infect Immun 2006, 74: 5826-5833.PubMedCentralCrossRefPubMed

41.

Panthel K, Meinel KM, Sevil Domènech VE, Trülzsch K, Rüssmann H: Salmonella type III-mediated heterologous antigen delivery: a versatile oral vaccination strategy to induce cellular immunity against infectious agents and tumors. Int J Med Microbiol 2008, 298: 99-103.CrossRefPubMed

42.

Norris PJ, Moffett HF, Yang OO, Kaufmann DE, Clark MJ, Addo MM, Rosenberg ES: Beyond help: direct effector functions of human immunodeficiency virus type 1-specific CD4(+) T cells. J Virol 2004, 78: 8844-8851.PubMedCentralCrossRefPubMed

43.

Jansen CA, van Baarle D, Miedema F: HIV-specific CD4+ T cells and viremia: who's in control? Trends Immunol 2006, 27: 119-124.CrossRefPubMed

44.

Kalams SA, Buchbinder SP, Rosenberg ES, Billingsley JM, Colbert DS, Jones NG, Shea AK, Trocha AK, Walker BD: Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection. J Virol 1999, 73: 6715-6720.PubMedCentralPubMed

45.

Emu B, Sinclair E, Favre D, Moretto WJ, Hsue P, Hoh R, Martin JN, Nixon DF, McCune JM, Deeks SG: Phenotypic, functional, and kinetic parameters associated with apparent T-cell control of human immunodeficiency virus replication in individuals with and without antiretroviral treatment. J Virol 2005, 79: 14169-14178.PubMedCentralCrossRefPubMed

46.

Martinez V, Costagliola D, Bonduelle O, N'go N, Schnuriger A, Theodorou I, Clauvel JP, Sicard D, Agut H, Debre P, Rouzioux C, Autran B: Combination of HIV-1-specific CD4 Th1 cell responses and IgG2 antibodies is the best predictor for persistence of long-term nonprogression. J Infect Dis 2005, 191: 2053-2063.CrossRefPubMed

47.

Lichterfeld M, Kaufmann DE, Yu XG, Mui SK, Addo MM, Johnston MN, Cohen D, Robbins GK, Pae E, Alter G, Wurcel A, Stone D, Rosenberg ES, Walker BD, Altfeld M: Loss of HIV-1-specific CD8+ T cell proliferation after acute HIV-1 infection and restoration by vaccine-induced HIV-1-specific CD4+ T cells. J Exp Med 2004, 200: 701-712.PubMedCentralCrossRefPubMed

48.

Hasenkrug KJ, Brooks DM, Robertson MN, Srinivas RV, Chesebro B: Immunoprotective determinants in friend murine leukemia virus envelope protein. Virology 1998, 248: 66-73.CrossRefPubMed

49.

Orentas RJ, Hildreth JE, Obah E, Polydefkis M, Smith GE, Clements ML, Siliciano RF: Induction of CD4+ human cytolytic T cells specific for HIV-infected cells by a gp160 subunit vaccine. Science 1990, 248: 1234-1237.CrossRefPubMed

50.

Manickan E, Francotte M, Kuklin N, Dewerchin M, Molitor C, Gheysen D, Slaoui M, Rouse BT: Vaccination with recombinant vaccinia viruses expressing ICP27 induces protective immunity against herpes simplex virus through CD4+ Th1+ T cells. J Virol 1995, 69: 4711-4716.PubMedCentralPubMed

51.

Hasenkrug KJ, Dittmer U: The role of CD4 and CD8 T cells in recovery and protection from retroviral infection: lessons from the Friend virus model. Virology 2000, 272: 244-249.CrossRefPubMed

52.

Zaunders JJ, Dyer WB, Wang B, Munier ML, Miranda-Saksena M, Newton R, Moore J, Mackay CR, Cooper DA, Saksena NK, Kelleher AD: Identification of circulating antigen-specific CD4+ T lymphocytes with a CCR5+, cytotoxic phenotype in an HIV-1 long-term nonprogressor and in CMV infection. Blood 2004, 103: 2238-2247.CrossRefPubMed

53.

Norris PJ, Sumaroka M, Brander C, Moffett HF, Boswell SL, Nguyen T, Sykulev Y, Walker BD, Rosenberg ES: Multiple effector functions mediated by human immunodeficiency virus-specific CD4(+) T-cell clones. J Virol 2001, 75: 9771-9779.PubMedCentralCrossRefPubMed

54.

Huber M, Trkola A: Humoral immunity to HIV-1: neutralization and beyond. J Intern Med 2007, 262: 5-25.CrossRefPubMed

Title: Oral vaccination with a recombinant Salmonella vaccine vector provokes systemic HIV-1 subtype C Gag-specific CD4+ Th1 and Th2 cell immune responses in mice
Authors: Nyasha Chin'ombe
William R Bourn
Anna-Lise Williamson
Enid G Shephard
Publication date: 01-12-2009
Publisher: BioMed Central
Published in: Virology Journal / Issue 1/2009
Electronic ISSN: 1743-422X
DOI: https://doi.org/10.1186/1743-422X-6-87

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2009

Avian influenza virus (H5N1); effects of physico-chemical factors on its survival

Hepatitis C virus core protein induces apoptosis-like caspase independent cell death

Towards a sane and rational approach to management of Influenza H1N1 2009

Analysis of a conserved RGE/RGD motif in HCV E2 in mediating entry

Influenza virus antigenic variation, host antibody production and new approach to control epidemics

Properties of virion transactivator proteins encoded by primate cytomegaloviruses

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials